Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

November 12, 2026 updated by: Immorna Biotherapeutics, Inc.

Randomized, Double-Blinded, Placebo-Controlled Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of Two Doses of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105) in Healthy Participants

Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

72

Phase

  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • (1) Gender: Male or female; (2) Age: ≥ 40 years of age at screening. (3) Status: Healthy participants. (4) Subject agrees not to receive any other herpes zoster vaccine while participating in this study.

    (5) All Laboratory values required for screening prior to study enrollment are within normal limits or abnormal without clinical significance as judged by the investigator.

    (6) Female participants must meet the following criteria:

    • Surgically sterile or postmenopausal for ≥ 2 years, or women of childbearing potential (premenopausal or postmenopausal for < 2 years) who have a negative pregnancy test and are willing to use effective contraception from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.

    • Agree not to breastfeed from the first administration of investigational vaccine/placebo to at least 3 months after the full-course vaccination.

      (7) Male participants should meet the following criteria: agree to use effective contraception and not to donate sperms from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.

      (8) Able to fully understand and voluntarily sign the informed consent form.

Exclusion Criteria:

  • (1) Participants who have a history of herpes zoster or are currently diagnosed with herpes zoster, or have a history of chickenpox, or a history of close contact with chickenpox/herpes zoster patients within 30 days before enrollment.

    (2) History of chickenpox or herpes zoster vaccination. (3) Hypersensitivity to any component of the investigational vaccine/placebo, or any previous serious reaction to vaccination, or a history of serious allergic disease.

    (4) Fever within 3 days prior to enrollment, acute illness or acute exacerbation of chronic illness within 7 days prior to enrollment, or taking antipyretic, analgesic, and anti-allergic drugs within 3 days prior to enrollment.

    (5) History of significant cardiac disease, or myocarditis or pericarditis. (6) At present, participants with severe liver and kidney diseases, spleen dysfunction or asplenia, hypertension that cannot be controlled by drugs, diabetes with serious complications and other chronic diseases are currently suffering.

    (7) Use of whole blood, blood products, or immunoglobulins within 3 months prior to vaccination or planned use during the study.

    (8) Has received any inactive vaccine within 14 days prior to the first dose of vaccine.

    (9) Received the following within 28 days prior to the first dose of vaccine: Any live/mRNA vaccine; Immunomodulators or immunosuppressive drugs; Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor; Receiving systemic corticosteroids for 3 or more consecutive days. (Note: Study participants are permitted to receive long-term systemic prednisone at a dose ≤10 mg/day, or systemic corticosteroids equivalent to prednisone. Topical medications such as ointments, eye drops, inhalants or nasal sprays are allowed, provided that the topical medications should not exceed the recommended dose in the instructions and there are no signs of systemic exposure.) (10) Have confirmed or suspected immunosuppression, immunodeficiency, or autoimmune disease.

    (11) Positive screening test for HIV antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies.

    (12) Known history of active or latent tuberculosis (Mycobacterium tuberculosis).

    (13) Axillary temperature > 37.0 °C at enrollment. (14) Participation in another drug, device, or other vaccine clinical trial within 30 days prior to the first dose of investigational vaccine/placebo or planned participation during the study period.

    (15) Participants with dermatologic condition that could affect local solicited adverse reaction assessments (e.g., tattoos, psoriasis, patches affecting skin over the deltoid area).

    (16) Participants with contraindications to IM injection. (17) The investigator considers that there are other situations unsuitable for participating in this study, including but not limited to failure to participate in follow-up according to the study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low-dose JCXH-105

Participants receive low dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

Placebo Comparator: Low-dose placebo

Participants receive low dose of placebo

Placebo (sodium chloride injection) as control

Experimental: Medium-dose JCXH-105

Participants receive medium dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

Placebo Comparator: Medium-dose placebo

Participants receive medium dose of placebo

Placebo (sodium chloride injection) as control

Experimental: High-dose JCXH-105

Participants receive high dose of JCXH-105

Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

Placebo Comparator: High-dose placebo

Participants receive high dose of placebo

Placebo (sodium chloride injection) as control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serious adverse events (SAEs)
Time Frame: From Day 1 post- administration through 360 days after the full-course vaccination

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

From Day 1 post- administration through 360 days after the full-course vaccination
Solicited local injection site adverse events
Time Frame: Within 14 days after each dose of investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 14 days after each dose of investigational vaccine/placebo
Solicited systemic adverse events
Time Frame: Within 14 days after each dose of the investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 14 days after each dose of the investigational vaccine/placebo
Unsolicited AEs
Time Frame: Within 30 days after each dose of the investigational vaccine/placebo

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

Within 30 days after each dose of the investigational vaccine/placebo
Laboratory parameters
Time Frame: On the third day after each dose of the investigational vaccine/placebo

Clinically significant abnormal changes of laboratory parameters compared with pre-vaccination

On the third day after each dose of the investigational vaccine/placebo
Adverse events of special interest (AESIs)
Time Frame: From Day 1 post administration through 360 days after the full-course vaccination

Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

From Day 1 post administration through 360 days after the full-course vaccination

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

March 1, 2028

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • JCXH-105-002

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.